Aurinia Pharmaceuticals Inc (AUPH) is a publicly traded Healthcare sector company. As of May 19, 2026, AUPH trades at $15.65 with a market cap of $1.97B and a P/E ratio of 6.86. AUPH moved +0.51% today. Year to date, AUPH is +1.63%; over the trailing twelve months it is +90.48%. Its 52-week range spans $6.55 to $16.88. Analyst consensus is buy with an average price target of $16.00. Rallies surfaces AUPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aurinia Pharmaceuticals Completes $41.2M Tender Offer Acquiring 80.24% of Kezar Shares: Aurinia Pharmaceuticals acquired 5,927,580 Kezar shares, representing 80.24% of outstanding stock, through a $6.955 cash tender plus one contingent value right per share. The transaction totaled $41.2 million in value and fulfilled the majority-of-outstanding-shares condition required under the offer.
| Metric | Value |
|---|---|
| Price | $15.65 |
| Market Cap | $1.97B |
| P/E Ratio | 6.86 |
| EPS | $2.26 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.88 |
| 52-Week Low | $6.55 |
| Volume | 323.13K |
| Avg Volume | 0 |
| Revenue (TTM) | $298.30M |
| Net Income | $298.21M |
| Gross Margin | 89.74% |
4 analysts cover AUPH: 0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.00.